View Single Post
Old 04-08-2010, 09:32 AM
Conductor71's Avatar
Conductor71 Conductor71 is offline
Senior Member
 
Join Date: Jul 2009
Location: Michigan
Posts: 1,474
15 yr Member
Conductor71 Conductor71 is offline
Senior Member
Conductor71's Avatar
 
Join Date: Jul 2009
Location: Michigan
Posts: 1,474
15 yr Member
Default Seems a big deal

Hmmm...why isn't TEVA jumping all over this? It seems to me that they could even reformulate Azilect with ECGC and market it as truly neuroproctive. This study sounds way more conclusive than the recent ADAGIO delayed start research that showed conflicting results. In fact, this study rather supports the ADAGIO finding that Azilect was neuroprotective at 1 mg only (no benefit for people at 2 mg).

I have a stash of Azilect samples in my hall closet. I had to stop taking it due to joint pain side effect; the White Rat in me is oh so tempted to now experiment with this.

Also wonder how this low, below therapeutic dose finding relates to the DX and Naltrexone approach to neuroprotection?

Laura
Conductor71 is offline   Reply With QuoteReply With Quote